Sign In
Buy MGNX
$4.69
+0.110 (+2.40%)
At Close: Jun 23, 2026
MacroGenics Announces Flotetuzumab and Tebotelimab Presentations at the ASH Annual Meeting 2020
02:30pm, Wednesday, 04'th Nov 2020
ROCKVILLE, MD, Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-base
MacroGenics Announces Date of Third Quarter 2020 Financial Results Conference Call
04:30pm, Wednesday, 28'th Oct 2020
ROCKVILLE, MD, Oct. 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-b
Short Interest in MacroGenics, Inc. (NASDAQ:MGNX) Grows By 18.0%
01:16am, Tuesday, 20'th Oct 2020
MacroGenics, Inc. (NASDAQ:MGNX) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 4,000,000 shares, a
Sanders Morris Harris LLC Buys Shares of 20,915 MacroGenics, Inc. (NASDAQ:MGNX)
06:36am, Monday, 19'th Oct 2020
Sanders Morris Harris LLC bought a new stake in MacroGenics, Inc. (NASDAQ:MGNX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). Th
Leap Therapeutics Initiates Trial, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:LPTX)
07:42pm, Friday, 25'th Sep 2020
Leap Therapeutics initiates Phase 2a trial for DKN-01. MacroGenics reports progress on MGA012 development.
MacroGenics Inc (NASDAQ:MGNX) Shares Purchased by Cubist Systematic Strategies LLC
08:52am, Saturday, 19'th Sep 2020
Cubist Systematic Strategies LLC raised its stake in shares of MacroGenics Inc (NASDAQ:MGNX) by 16,396.7% during the second quarter, according to the company in its most recent 13F filing with the SEC
Tudor Investment Corp Et Al Invests $257,000 in MacroGenics Inc (NASDAQ:MGNX)
07:26am, Friday, 18'th Sep 2020
Tudor Investment Corp Et Al purchased a new position in MacroGenics Inc (NASDAQ:MGNX) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 9,207 sha
Trexquant Investment LP Invests $882,000 in MacroGenics Inc (NASDAQ:MGNX)
07:32am, Sunday, 23'rd Aug 2020
Trexquant Investment LP acquired a new position in shares of MacroGenics Inc (NASDAQ:MGNX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange
MacroGenics to Participate in Upcoming Investor Conferences
08:30pm, Wednesday, 05'th Aug 2020
ROCKVILLE, MD, Aug. 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based
Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
12:00am, Tuesday, 04'th Aug 2020
Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
News Flash: Analysts Just Made A Notable Upgrade To Their MacroGenics, Inc. (NASDAQ:MGNX) Forecasts
02:21pm, Sunday, 02'nd Aug 2020
Shareholders in MacroGenics, Inc. (NASDAQ:MGNX) may be thrilled to learn that the analysts have just delivered a major...
MacroGenics (MGNX) Q2 2020 Earnings Call Transcript
07:03am, Saturday, 01'st Aug 2020
MGNX earnings call for the period ending June 30, 2020.
MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q2 2020 Results - Earnings Call Transcript
09:35pm, Friday, 31'st Jul 2020
MacroGenics, Inc. (NASDAQ:MGNX) Q2 2020 Earnings Conference Call July 30, 2020 04:30 PM ET Company Participants Anna Krassowska - Investor Relations Scott Koenig - President and CEO Jim Karrels - CFO
Is MacroGenics, Inc. (NASDAQ:MGNX) Trading At A 37% Discount?
10:55am, Friday, 31'st Jul 2020
In this article we are going to estimate the intrinsic value of MacroGenics, Inc. (NASDAQ:MGNX) by taking the expected...
MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates
10:40pm, Thursday, 30'th Jul 2020
MacroGenics (MGNX) delivered earnings and revenue surprises of -6.82% and 42.78%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
